Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
SY Cindy Yang, SC Lien, BX Wang… - Nature …, 2021 - nature.com
Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to
predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer …
predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer …
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …
cancer. However, existing biomarkers do not reliably predict treatment response across …
Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …
Early assessment of lung cancer immunotherapy response via circulating tumor DNA
SB Goldberg, A Narayan, AJ Kole, RH Decker… - Clinical Cancer …, 2018 - AACR
Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …
Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition
Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …
Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non–small-cell lung cancer treated with immune checkpoint inhibitors
DM Vega, KK Nishimura, N Zariffa… - JCO Precision …, 2022 - ascopubs.org
PURPOSE As immune checkpoint inhibitors (ICI) become increasingly used in frontline
settings, identifying early indicators of response is needed. Recent studies suggest a role for …
settings, identifying early indicators of response is needed. Recent studies suggest a role for …
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy
V Anagnostou, BV Landon, JE Medina… - Science translational …, 2022 - science.org
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics, triggering
studies to understand the molecular and cellular wiring of response and resistance. Our …
studies to understand the molecular and cellular wiring of response and resistance. Our …
[HTML][HTML] Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
M Hwang, JV Canzoniero, S Rosner… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Despite treatment advancements with immunotherapy, our understanding of
response relies on tissue-based, static tumor features such as tumor mutation burden (TMB) …
response relies on tissue-based, static tumor features such as tumor mutation burden (TMB) …
Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types
R Cristescu, M Nebozhyn, C Zhang, A Albright… - Clinical Cancer …, 2022 - AACR
Purpose: To explore relationships between biological gene expression signatures and
pembrolizumab response. Experimental Design: RNA-sequencing data on baseline tumor …
pembrolizumab response. Experimental Design: RNA-sequencing data on baseline tumor …
Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non–small-cell lung cancer treated with immune checkpoint inhibitors
S Weber, P van der Leest, HC Donker… - JCO Precision …, 2021 - ascopubs.org
PURPOSE Immune checkpoint inhibitors (ICIs) are increasingly being used in non–small-
cell lung cancer (NSCLC), yet biomarkers predicting their benefit are lacking. We evaluated …
cell lung cancer (NSCLC), yet biomarkers predicting their benefit are lacking. We evaluated …